Abstract
Alzheimer’s disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer’s disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
Keywords: Acetylcholinesterase, Alzheimer’s disease, Amyloid plaques, Cholinergic impulse, Dementia, ROS.
Letters in Drug Design & Discovery
Title:Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Volume: 11 Issue: 2
Author(s): Luciana Scotti, Francisco Jaime Bezerra Mendonça Junior, Marcelo Sobral da Silva, Ivan R. Pitta and Marcus Tullius Scotti
Affiliation:
Keywords: Acetylcholinesterase, Alzheimer’s disease, Amyloid plaques, Cholinergic impulse, Dementia, ROS.
Abstract: Alzheimer’s disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer’s disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
Export Options
About this article
Cite this article as:
Scotti Luciana, Jaime Bezerra Mendonça Junior Francisco, Sobral da Silva Marcelo, R. Pitta Ivan and Tullius Scotti Marcus, Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review, Letters in Drug Design & Discovery 2014; 11 (2) . https://dx.doi.org/10.2174/15701808113109990063
DOI https://dx.doi.org/10.2174/15701808113109990063 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Closer Look at Protein Transduction Domains as a Tool in Drug Delivery
Current Nanoscience Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Pediatric Health Effects of Chronic Exposure to Extremely Low Frequency Electromagnetic Fields
Current Pediatric Reviews Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Meet Our Editor
Current Gene Therapy Critical Aspects to be Considered Prior to Large-Scale Production of Peptides
Current Protein & Peptide Science Drugs of Abuse in Pregnancy, Poor Neonatal Development, and Future Neurodegeneration. Is Oxidative Stress the Culprit?
Current Pharmaceutical Design 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Systematic Review and Quality Appraisal of International Guidelines on Perinatal Care of Extremely Premature Infants
Current Pediatric Reviews Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Reviews on Recent Clinical Trials Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Mitochondrial Uncoupler Proteins
Current Enzyme Inhibition The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases
Current Pharmaceutical Design